Clinical study of Juheli in treatment and prevention of chemotherapy-induced thrombocytopenia

To study the efficiency and toxicity of Juheli(recombinant human interleukin-11,rhIL-11)in the treatment of chemotherap-yinduced thrombocytopenia. Forty-seven patients with carcinoma were randomly divided into AB group and BA group. In cycle A,Juheli was given 50 μg/(kg·d) till the platelet count reached ≥100×109 L -1 ,and cycle B received no treatment. The efficacy and toxicity were observed. The minimum of platelet in cycle A was ( 107.9±30.2) ×109 L -1 ;the minimum of platelet in cycle B was (56.4±30.3)×109 L -1 . Conclusion:Juheli could elevate platelet counts with acceptable mild side-effects and decrease complication of bleeding so that the Chinese product of rhIL-11 facilitates chemotherapy significantly.